Skip to main content

Table 3 Characteristics of antiretroviral treatment-naive HIV/HBV Co-infected patients with undetectable HBVDNA compared to those with detectable HBV DNA

From: Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients

Characteristic HBV DNA < 20 IU/mL HBV DNA ≥ 20 IU/mL P-value T test P-value Wilcoxon rank sum test
(N = 64) (N = 88)
Mean (SD) age (years) 39.6 (8.0) 37.7 (10.4) 0.616 0.288
Mean (SD) weight (kg) 66.2 (9.5) 58.8 (13.4) 0.116 0.092
Mean (SD) BMI (kg/m2) 23.7 (4.9) 21.6 (4.4) 0.184 0.209
Mean (SD) CD4 count (cells/uL) 561.7 (504.5) 338.8 (302.7) 0.228 0.144
  n (%) n (%) P-value Chi square P-value Fisher
Male sex 4 (12.5 %) 28 (87.5 %) 0.701 0.728
Ethnicity    0.404 0.381
 Akan 6 (16.2 %) 31 (83.8 %)   
 Ewe 0 (0.0 %) 15 (100.0 %)   
 Ga 1 (12.5 %) 7 (87.5 %)   
 Other 2 (9.5 %) 19 (90.5 %)   
WHO HIV stage    0.265 0.174
 1 & 2 2 (5.1 %) 37 (94.9 %)   
 3 & 4 7 (16.3 %) 36 (83.7 %)   
HBeAg positive 0 (0.0 %) 19 (100.0 %) 0.083 0.110
HBeAb positive 9 (13.6 %) 57 (86.4 %) 0.107 0.193
HBeAg/E Ab combination    0.361 0.339
HBeAg positive/Ab negative 0 (0.0 %) 16 (100.0 %)   
HBeAg negative/Ab positive 9 (14.3 %) 54 (85.7 %)   
HBeAg negative/Ab negative 0 (0.0 %) 1 (100.0 %)   
HBeAg positive/Ab positive 0 (0.0 %) 3 (100.0 %)   
HBcIgM positive 0 (0.0 %) 1 (100.0 %) 0.726 1.000
Alanine aminotransferase    0.622 0.731
 Normal (5–40 U/L) 6 (12.2 %) 43 (87.8 %)   
 Elevated > ULN 3 (8.8 %) 31 (91.2 %)   
Aspartate aminotransferase    0.320 0.473
 Normal (5–50 U/L) 7 (13.5 %) 45 (86.5 %)   
 Elevated > ULN 2 (6.5 %) 29 (93.6 %)   
Albumin    0.945 1.000
 Normal (36–50 g/L) 4 (11.1 %) 42 (89.4 %)   
 Low < LLN 5 (10.6 %) 19 (54.3 %)   
  1. BMI body mass index
  2. HBeAg/Ab Hepatitis B e Antigen/Antibody
  3. HBcIgM Hepatitis B core IgM
  4. ULN: upper limit of normal
  5. LLN lower limit of normal